Immunization issues in pediatric travelers

References

• Centers for Disease Control and Prevention. Health Information for International Travel. US Department of Health and Human Services, Public Health Service, GA, USA (2008).
   Google Scholar
• Romagnani S. Th1/Th2 cells. Inflamm. Bowel Dis.5(4), 285–294 (1999).
   PubMed Web of Science ®Google Scholar
• Morein B, Blomqvist G, Hu K. Immune responsiveness in the neonatal period. J. Comp. Pathol.137(Suppl. 1), S27–S31 (2007).
   PubMed Web of Science ®Google Scholar
• McGuirk P, Mills KH. Pathogen-specific regulatory T cells provoke a shift in the Th1/Th2 paradigm in immunity to infectious diseases. Trends Immunol.23(9), 450–455 (2002).
   PubMed Web of Science ®Google Scholar
• Edwards KM, Burns VE, Adkins AE, Carroll D, Drayson M, Ring C. Meningococcal A vaccination response is enhanced by acute stress in men. Psychosom. Med.70(2), 147–151 (2008).
   PubMedGoogle Scholar
• Kew OM, Nottay BK, Hatch MH, Nakano JH, Obijeski JF. Multiple genetic changes can occur in the oral poliovaccines upon replication in humans. J. Gen. Virol.56(Pt 2), 337–347 (1981).
   PubMed Web of Science ®Google Scholar
• Geurtsen J, Banus HA, Gremmer ER et al. Lipopolysaccharide analogs improve efficacy of acellular pertussis vaccine and reduce type I hypersensitivity in mice. Clin. Vaccine Immunol.14(7), 821–829 (2007).
   PubMedGoogle Scholar
• Audran R, Cachat M, Lurati F et al. Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen. Infect. Immun.73(12), 8017–8026 (2005).
   PubMed Web of Science ®Google Scholar
• Leitner WW, Ying H, Restifo NP. DNA and RNA-based vaccines: principles, progress and prospects. Vaccine18(9–10), 765–777 (1999).
   PubMed Web of Science ®Google Scholar
• Gilbert SC, Moorthy VS, Andrews L et al. Synergistic DNA–MVA prime–boost vaccination regimes for malaria and tuberculosis. Vaccine24(21), 4554–4561 (2006).
   PubMed Web of Science ®Google Scholar
• Hokey DA, Weiner DB. DNA vaccines for HIV: challenges and opportunities. Springer Semin. Immunopathol.28(3), 267–279 (2006).
   PubMed Web of Science ®Google Scholar
• Konishi E, Kosugi S, Imoto J. Dengue tetravalent DNA vaccine inducing neutralizing antibody and anamnestic responses to four serotypes in mice. Vaccine24(12), 2200–2207 (2006).
   PubMed Web of Science ®Google Scholar
• Stauffer WC, Christenson JC, Fischer PR. Preparing children for international travel. Travel Med. Infect. Dis.6(3), 101–113 (2008).
   PubMedGoogle Scholar
• Siegrist CA. Neonatal and early life vaccinology. Vaccine19(25–26), 3331–3346 (2001).
   PubMed Web of Science ®Google Scholar
• Decker MD, Edwards KM. Haemophilus influenzae type b vaccines: history, choice and comparisons. Pediatr. Infect. Dis. J.17(Suppl. 9), S113–S116 (1998).
   PubMed Web of Science ®Google Scholar
• Siegrist CA. The challenges of vaccine responses in early life: selected examples. J. Comp. Pathol.137(Suppl. 1), S4–S9 (2007).
   PubMed Web of Science ®Google Scholar
• Mast EE, Margolis HS, Fiore AE et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part 1: immunization of infants, children, and adolescents. MMWR Recom. Rep.54(RR-16), 1–31 (2005); erratum in MMWR Morb. Mortal. Wkly Rep.55(6), 158–159 (2006).
   PubMedGoogle Scholar
• World Health Organization. BCG vaccine. WHO position paper. Wkly Epidemiol. Rec.79(4), 27–38 (2004).
   PubMedGoogle Scholar
• De-xiang D, Xi-min H, Wan-sun L et al. Immunization of neonates with trivalent oral poliomyelitls vaccine (Sabin). Bull. World Health Organ.64(6), 853–860 (1986).
   PubMedGoogle Scholar
• Pickering LK BC, Long SS, McMillan JA. Red Book: 2006 Report of the Committee on Infectious Diseases American Academy of Pediatrics. Elk Grove Village, IL, USA (2006).
   Google Scholar
• Ruggeberg JU, Collins C, Clarke P et al. Immunogenicity and induction of immunological memory of the heptavalent pneumococcal conjugate vaccine in preterm UK infants. Vaccine25(2), 264–271 (2007).
   PubMed Web of Science ®Google Scholar
• Lau YL, Tam AY, Ng KW et al. Response of preterm infants to hepatitis B vaccine. J. Pediatr.121(6), 962–965 (1992).
   PubMed Web of Science ®Google Scholar
• Saari TN; American Academy of Pediatrics Committee on Infectious Diseases. Immunization of preterm and low birth weight infants. Pediatrics112(1), 193–198 (2003).
   PubMed Web of Science ®Google Scholar
• Khalak R, Pichichero ME, D’Angio CT. Three-year follow-up of vaccine response in extremely preterm infants. Pediatrics101(4), 597–603 (1998).
   PubMedGoogle Scholar
• Bonhoeffer J, Siegrist CA, Heath PT. Immunisation of premature infants. Arch. Dis. Child.91(11), 929–935 (2006).
   PubMed Web of Science ®Google Scholar
• Kirmani KI, Lofthus G, Pichichero ME, Voloshen T, D’Angio CT. Seven-year follow-up of vaccine response in extremely premature infants. Pediatrics109(3), 498–504 (2002).
   PubMed Web of Science ®Google Scholar
• Broder KR, Cortese MM, Iskander JK et al. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recom. Rep.55(RR-3), 1–34 (2006).
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. Revised recommendations of the Advisory Committee on Immunization Practices to vaccinate all persons aged 11–18 years with meningococcal conjugate vaccine. MMWR56(31), 794–795 (2007).
   PubMedGoogle Scholar
• Marin M, Guris D, Chaves SS, Schmid S, Seward JF; Advisory Committee on Immunization Practices (ACIP). Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recom. Rep.56(RR-4), 1–40 (2007).
   PubMedGoogle Scholar
• Anonymous. 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR Recom. Rep.43(12), 1–10 (1994).
   Google Scholar
• Levin MJ, Gershon AA, Weinberg A et al. Immunization of HIV-infected children with varicella vaccine. J. Pediatr.139(2), 305–310 (2001).
   PubMed Web of Science ®Google Scholar
• Receveur MC, Thiebaut R, Vedy S, Malvy D, Mercie P, Bras ML. Yellow fever vaccination of human immunodeficiency virus-infected patients: report of 2 cases. Clin. Infect. Dis.31(3), E7–E8 (2000).
   PubMed Web of Science ®Google Scholar
• Gowda R, Cartwright K, Bremner JA, Green ST. Yellow fever vaccine: a successful vaccination of an immunocompromised patient. Eur. J. Haematol.72(4), 299–301 (2004).
   PubMed Web of Science ®Google Scholar
• Sibailly TS, Wiktor SZ, Tsai TF et al. Poor antibody response to yellow fever vaccination in children infected with human immunodeficiency virus type 1. Pediatr. Infect. Dis. J.16(12), 1177–1179 (1997).
   PubMed Web of Science ®Google Scholar
• Thaithumyanon P, Punnahitananda S, Thisyakorn U, Praisuwanna P, Ruxrungtham K. Immune responses to measles immunization and the impacts on HIV-infected children. Southeast Asian J. Trop. Med. Public Health31(4), 658–662 (2000).
   PubMedGoogle Scholar
• Watson DA. Pretravel health advice for asplenic individuals. J. Travel Med.10(2), 117–121 (2003).
   PubMedGoogle Scholar
• Lipman HM. Preventing severe infection after splenectomy: risk of malaria and meningitis increases with asplenia. BMJ331(7516), 576 (2005).
   PubMedGoogle Scholar
• Newland A, Provan D, Myint S. Preventing severe infection after splenectomy. BMJ331(7514), 417–418 (2005).
   PubMed Web of Science ®Google Scholar
• Weber DJ, Rutala WA. Immunization of immunocompromised persons. Immunol. Allergy Clin. North Am.23(4), 605–634 (2003).
   PubMedGoogle Scholar
• Booy R, Aitken SJ, Taylor S et al. Immunogenicity of combined diphtheria, tetanus, and pertussis vaccine given at 2, 3, and 4 months versus 3, 5, and 9 months of age. Lancet339(8792), 507–510 (1992).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. CDC Health Information for International Travel. US Department of Health and Human Services, GA, USA (2007).
   Google Scholar
• Solomon T, Dung NM, Kneen R, Gainsborough M, Vaughn DW, Khanh VT. Neurological aspects of tropical disease: Japanese encephalitis. J. Neurol. Neurosurg. Psychiatry68(4), 405–415 (2000).
   PubMed Web of Science ®Google Scholar
• Pebody RG, Gay NJ, Hesketh LM et al. Immunogenicity of second dose measles–mumps–rubella (MMR) vaccine and implications for serosurveillance. Vaccine20(7–8), 1134–1140 (2002).
   PubMedGoogle Scholar
• Hayden GF. Measles vaccine failure. A survey of causes and means of prevention. Clin. Pediatr. (Philadelphia)18(3), 155–156; 161–163; 167 (1979).
   PubMedGoogle Scholar
• Watson JC, Hadler SC, Dykewicz CA, Reef S, Phillips L. Measles, mumps, and rubella – vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recom. Rep.47(RR-8), 1–57 (1998).
   PubMedGoogle Scholar
• Kuter B, Matthews H, Shinefield H et al. Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Pediatr. Infect. Dis. J.23(2), 132–137 (2004).
   PubMed Web of Science ®Google Scholar
• Goh P, Lim FS, Han HH, Willems P. Safety and immunogenicity of early vaccination with two doses of tetravalent measles–mumps–rubella–varicella (MMRV) vaccine in healthy children from 9 months of age. Infection35(5), 326–333 (2007).
   PubMed Web of Science ®Google Scholar
• Vogel C, Funk M. Measles quarantine; the individual and the public. J. Travel Med.15(2), 65–67 (2008).
   PubMedGoogle Scholar
• Munoz J, Alonso D, Vilella A, Naniche D, Costa J, Gascon J. Measles in travelers: are we aware enough? J. Travel Med.15(2), 124–125 (2008).
   PubMedGoogle Scholar
• Jenson HB. The changing picture of hepatitis A in the United States. Curr. Opin. Pediatr.16(1), 89–93 (2004).
   PubMedGoogle Scholar
• Innis BL, Snitbhan R, Kunasol P et al. Protection against hepatitis A by an inactivated vaccine. JAMA271(17), 1328–1334 (1994).
   PubMed Web of Science ®Google Scholar
• Troisi CL, Blaine Hollinger F, Krause DS, Pickering LK. Immunization of seronegative infants with hepatitis A vaccine (HAVRIX®; SKB): a comparative study of two dosing schedules. Vaccine15(15), 1613–1617 (1997).
   PubMed Web of Science ®Google Scholar
• Victor JC, Monto AS, Surdina TY et al. Hepatitis A vaccine versus immune globulin for postexposure prophylaxis. N. Engl. J. Med.357(17), 1685–1694 (2007).
   PubMed Web of Science ®Google Scholar
• Van Damme P, Banatvala J, Fay O et al. Hepatitis A booster vaccination: is there a need? Lancet362(9389), 1065–1071 (2003).
   PubMed Web of Science ®Google Scholar
• Dagan R, Amir J, Mijalovsky A et al. Immunization against hepatitis A in the first year of life: priming despite the presence of maternal antibody. Pediatr. Infect. Dis. J.19(11), 1045–1052 (2000).
   PubMed Web of Science ®Google Scholar
• Bell BP, Negus S, Fiore AE et al. Immunogenicity of an inactivated hepatitis A vaccine in infants and young children. Pediatr. Infect. Dis. J.26(2), 116–122 (2007).
   PubMed Web of Science ®Google Scholar
• Stojanov S, Liese JG, Belohradsky BH et al. Administration of hepatitis A vaccine at 6 and 12 months of age concomitantly with hexavalent (DTaP-IPV-PRP approximately T-HBs) combination vaccine. Vaccine25(43), 7549–7558 (2007).
   PubMed Web of Science ®Google Scholar
• Usonis V, Meriste S, Bakasenas V et al. Immunogenicity and safety of a combined hepatitis A and B vaccine administered concomitantly with either a measles–mumps–rubella or a diphtheria–tetanus–acellular pertussis-inactivated poliomyelitis vaccine mixed with a Haemophilus influenzae type b conjugate vaccine in infants aged 12–18 months. Vaccine23(20), 2602–2606 (2005).
   PubMed Web of Science ®Google Scholar
• McAnally TP, Ten Eyck RP. Influenza-like syndrome following typhoid immunization. Mil. Med.149(4), 200–201 (1984).
   PubMedGoogle Scholar
• Pounder DJ. Sudden, unexpected death following typhoid-cholera vaccination. Forensic Sci. Int.24(1), 95–98 (1984).
   PubMedGoogle Scholar
• Typhoid vaccines: WHO position paper. Wkly Epidemiol. Rec.83(6), 49–59 (2008).
   PubMedGoogle Scholar
• Wahdan MH, Serie C, Cerisier Y, Sallam S, Germanier R. A controlled field trial of live Salmonella typhi strain Ty21a oral vaccine against typhoid: three-year results. J. Infect. Dis.145(3), 292–295 (1982).
   PubMed Web of Science ®Google Scholar
• Horowitz H, Carbonaro CA. Inhibition of the Salmonella typhi oral vaccine strain, Ty21a, by mefloquine and chloroquine. J. Infect. Dis.166(6), 1462–1464 (1992).
   PubMedGoogle Scholar
• Kollaritsch H, Que JU, Kunz C, Wiedermann G, Herzog C, Cryz SJ Jr. Safety and immunogenicity of live oral cholera and typhoid vaccines administered alone or in combination with antimalarial drugs, oral polio vaccine, or yellow fever vaccine. J. Infect. Dis.175(4), 871–875 (1997).
   PubMed Web of Science ®Google Scholar
• Murphy JR, Grez L, Schlesinger L et al. Immunogenicity of Salmonella typhi Ty21a vaccine for young children. Infect. Immun.59(11), 4291–4293 (1991).
   PubMed Web of Science ®Google Scholar
• Klugman KP, Koornhof HJ, Robbins JB, Le Cam NN. Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine14(5), 435–438 (1996).
   PubMed Web of Science ®Google Scholar
• Lin FY, Ho VA, Khiem HB et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N. Engl. J. Med.344(17), 1263–1269 (2001).
   PubMed Web of Science ®Google Scholar
• Finne J, Leinonen M, Makela PH. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet2(8346), 355–357 (1983).
   PubMed Web of Science ®Google Scholar
• Tappero JW, Lagos R, Ballesteros AM et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA281(16), 1520–1527 (1999).
   PubMed Web of Science ®Google Scholar
• Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine20(Suppl. 1), S58–S67 (2001).
   PubMed Web of Science ®Google Scholar
• Lieberman JM, Chiu SS, Wong VK et al. Safety and immunogenicity of a serogroups A/C Neisseria meningitidis oligosaccharide–protein conjugate vaccine in young children. A randomized controlled trial. JAMA275(19), 1499–1503 (1996).
   PubMed Web of Science ®Google Scholar
• Snape MD, Perrett KP, Ford KJ et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA299(2), 173–184 (2008).
   PubMed Web of Science ®Google Scholar
• Marfin AA, Eidex RS, Kozarsky PE, Cetron MS. Yellow fever and Japanese encephalitis vaccines: indications and complications. Infect. Dis. Clin. North Am.19(1), 151–168 (2005).
   PubMed Web of Science ®Google Scholar
• Japanese encephalitis vaccines. Wkly Epidemiol. Rec.81(34/35), 331–340 (2006).
   PubMedGoogle Scholar
• Monath TP, Guirakhoo F, Nichols R et al. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): Phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J. Infect. Dis.188(8), 1213–1230 (2003).
   PubMed Web of Science ®Google Scholar
• Tauber E, Kollaritsch H, Korinek M et al. Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, Phase III, randomised controlled trial. Lancet370(9602), 1847–1853 (2007).
   PubMed Web of Science ®Google Scholar
• Takahashi H, Pool V, Tsai TF, Chen RT. Adverse events after Japanese encephalitis vaccination: review of post-marketing surveillance data from Japan and the United States. Vaccine18(26), 2963–2969 (2000).
   PubMed Web of Science ®Google Scholar
• Package insert. Japanese encephalitis virus vaccine inactivated. Aventis Pasteur Inc., PA, USA (1997).
   Google Scholar
• Hankins DG, Rosekrans JA. Overview, prevention, and treatment of rabies. Mayo Clinic Proc.79(5), 671–676 (2004).
   PubMed Web of Science ®Google Scholar
• Meslin F-X. Rabies as a traveler’s risk, especially in high-endemicity areas. J. Travel Med.12(Suppl. 1), S30–S40 (2005).
   PubMedGoogle Scholar
• Rabies vaccines. WHO position paper. Wkly Epidemiol. Rec.82(49–50), 425–435 (2007).
   PubMedGoogle Scholar
• Human rabies prevention – United States, 1999. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recom. Rep.48(RR-1), 1–21 (1999); erratum in MMWR Morb. Mortal. Wkly Rep.48(1), 16 (1999).
   Google Scholar
• Khawplod P, Wilde H, Benjavongkulchai M, Sriaroon C, Chomchey P. Immunogenicity study of abbreviated rabies preexposure vaccination schedules. J. Travel Med.14(3), 173–176 (2007).
   PubMed Web of Science ®Google Scholar
• Potasman I, Pick N, Stringer C, Zuckerman JN. Inadequate protection against yellow fever of children visiting endemic areas. Am. J. Trop. Med. Hyg.65(6), 954–957 (2001).
   PubMedGoogle Scholar
• Plotkin S, Orenstein W, Offit P (Eds). Yellow fever. In: Vaccines. WB Saunders, PA, USA (2004).
   Google Scholar
• Meegan J. Yellow fever vaccine. In: WHO Expanded Programme on Immunization. Document No: WHO/EPI/GEN/91.6 (1991).
   Google Scholar
• Fatal viral encephalitis following 17D yellow fever vaccine inoculation. Report of a case in a 3-year-old child. JAMA198(6), 671–672 (1966).
   PubMed Web of Science ®Google Scholar
• Plotkin S, Orenstein W, Offit P. Vaccines. WB Saunders, PA, USA (2004).
   Google Scholar
• Tosh PK, Boyce TG, Poland GA. Flu myths: dispelling the myths associated with live attenuated influenza vaccine. Mayo Clinic Proc.83(1), 77–84 (2008).
   PubMed Web of Science ®Google Scholar
• Steffen R, Acar J, Walker E, Zuckerman J. Cholera: assessing the risk to travellers and identifying methods of protection. Travel Med. Infect. Dis.1(2), 80–88 (2003).
   PubMedGoogle Scholar
• Hill DR, Ford L, Lalloo DG. Oral cholera vaccines: use in clinical practice. Lancet Infect. Dis.6(6), 361–373 (2006).
   PubMed Web of Science ®Google Scholar
• Qadri F, Chowdhury MI, Faruque SM et al. Peru-15, a live attenuated oral cholera vaccine, is safe and immunogenic in Bangladeshi toddlers and infants. Vaccine25(2), 231–238 (2007).
   PubMed Web of Science ®Google Scholar